FDA approves first treatment for breast cancer with a certain inherited genetic mutation

January 12, 2018 – The U.S. Food and Drug Administration today expanded the approved use of olaparib (tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast … (leggi tutto)